Leucine-based motif and clostridial neurotoxins

Details Leucine-based motif and clostridial neurotoxins Leucine-based motif and clostridial neurotoxins

2005-06-07

2005-06-07

Hayes, Robert C. (Department: 1647)

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

C424S239100

Reexamination Certificate

active

06903187

ABSTRACT:
Modified neurotoxin comprising neurotoxin including structural modification, wherein the structural modification alters the biological persistence, preferably the biological half-life, of the modified neurotoxin relative to an identical neurotoxin without the structural modification. The structural modification includes addition or deletion of a leucine-based motif or parts thereof. In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In another embodiment, methods of using the modified neurotoxin to treat biological disorders include treating autonomic disorders, neuromuscular disorders or pains.

REFERENCES:
patent: 4932936 (1990-06-01), Dykstra et al.
patent: 5437291 (1995-08-01), Pasricha et al.
patent: 5714468 (1998-02-01), Binder
patent: 5766605 (1998-06-01), Sanders et al.
patent: 5939070 (1999-08-01), Johnson et al.
patent: 5989545 (1999-11-01), Foster et al.
patent: 9416629 (1994-07-01), None
Radinger In “Peptide Hormones” (ed. J.A. Parsons) University Part Press, Baltimore, pp. 1-7, 1976.
Cai and Singh , “A Correlation Between Differential Structural Features and the Degree of Endopeptidase . . . ” Biochemistry (Washington) 2001; 40(15): 4693-4702.
Schantz, E.J., et al.,Properties and use of Botulinum Toxin and Other Microbial Neurotoxins in Medicine, Microbiological Reviews, Mar. 1992, vol. 56, No. 1, pp. 80-99.
Shin et al, “Phosphorylation-Dependent Down-Modulation . . . ” Journal of Biological Chemistry 266: 10658-10665, 1991.
Raciborska & Charlton, “Retention of Cleaved Synaptosome-Associated . . . ” Can J. Physiol, 77: 679-688, 1999.
Erdal et al, “Processing of Tetanus and Botulinum A . . . ” Naunyn-Schmiedeberg's Arch Pharmacol 351: 67-78, 1995.
Ragona et al, “Management of Parotid Sialocele . . . ” The Laryngoscope 109: 1344-1346, 1999.
Naumann et al, “Botulinum Toxin Type A in the Treatment . . . ” European Journal of Neurology 6: S111-S115, 1999.
Keller et al, “Persistence of Botulinum Neurotoxin . . . ” Federation of European Biochemical Societies Letters 456: 137-142, 1999.
Dietrich et al, “Regulation and Function of the CD3yDxxxLL Motif . . . ” Journal of Cell Biology 138: 271-281, 1997.
Geisler et al, “Leucine-Based Receptor Sorting Motifs . . . ” Journal of Biological Chemistry 273: 21316-21323, 1998.
Tan et al, “A Leucine-Based Motif Mediates the Endocytosis . . . ” Journal of Biological Chemistry 273: 17351-17360, 1998.
Liu et al, “Membrane Trafficking of Neurotransmitter . . . ” Trends in Cell Biology 9: 356-363, 1999.
Minton, “Molecular Genetics of Clostridial Neurotoxins” Springer-Verlag: Berlin, 1995, 161-194.
Binz et al, J. Biol. Chem. V 265, p. 9153-9158.
Fernandez-Salas, et al., “Plasma membrane localization signals in the light chain of botulinum neurotoxin,” Proc. Natl. Acad. Sci. USA (2004) 101:3208-3213.
Fernandez-Salas, et al., “Is the light chain subcellular localization an important factor in Botulinum toxin duration of action?” Movement Disorders (2004) 19:S23-S34.

Affiliated with

Also associated with

Rating

Leucine-based motif and clostridial neurotoxins does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Leucine-based motif and clostridial neurotoxins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Leucine-based motif and clostridial neurotoxins will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3512537